Skip to main content

XENE

Stock

XENE

Stock
Health Care
Biotechnology

Performance overview

XENE Price
Price Chart

Forward-looking statistics

Beta
0.64
Risk
36.12%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Company info

SectorHealth Care
IndustryBiotechnology
Employees247
Market cap$2.8B

Fundamentals

Enterprise value$1.9B
Revenue$7.5M
Revenue per employee
Profit margin0.00%
Debt to equity1.23

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.22
Dividend per share
Revenue per share$0.10
Avg trading volume (30 day)$44M
Avg trading volume (10 day)$70M
Put-call ratio

Macro factor sensitivity

Growth-1.4
Credit+4.6
Liquidity+3.2
Inflation-2.1
Commodities-1.3
Interest Rates-1.9

Valuation

Dividend yield0.00%
PEG Ratio-9.34
Price to sales340.29
P/E Ratio-9.34
Enterprise Value to Revenue248.11
Price to book3.62

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research (June 11, 2025)
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.

CNBC Television (March 31, 2025)
Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency

Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced new efficacy data supporting the Phase 3 development of XEN1101. XEN1101 rapidly reduced focal onset seizure frequency within one week for all doses compared with placebo.

Benzinga (June 23, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free